![[höher]](/style/images/multi_up.png)
Eine Ebene höherGruppiert nach:
Dokumententyp
| Veröffentlichungsdatum
Springe zu: Zeitschriftenartikel
Anzahl der Publikationen: 14
Zeitschriftenartikel
Nitz, Ulrike; Gluz, Oleg; Graeser, Monika; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Braun, Michael; Augustin, Doris; Potenberg, Jochem; Krauss, Katja; Schumacher, Claudia; Forstbauer, Helmut; Reimer, Toralf; Stefek, Andrea; Fischer, Hans Holger; Pelz, Enrico; Eulenburg, Christine zu; Kates, Ronald; Würstlein, Rachel; Kreipe, Hans Heinrich und Harbeck, Nadia
(2022):
De-escalated neoadjuvant pertuzumab plus trastuzumab therapy with or without weekly paclitaxel in HER2-positive, hormone receptor-negative, early breast cancer (WSG-ADAPT-HER2+/HR-): survival outcomes from a multicentre, open-label, randomised, phase 2 trial.
In: Lancet Oncology, Bd. 23, Nr. 5: S. 625-635
de Gregorio, Amelie; Janni, Wolfgang; Friedl, Thomas W. P.; Nitz, Ulrike; Rack, Brigitte; Schneeweiss, Andreas; Kates, Ronald; Fehm, Tanja; Kreipe, Hans; Christgen, Matthias; Kuemmel, Sherko; Trapp, Elisabeth; Wuerstlein, Rachel; Haertkopf, Andreas; Clemens, Michael; Reimer, Toralf; Haeberle, Lothar; Fasching, Peter A.; Gluz, Oleg und Harbeck, Nadia
(2022):
The impact of anthracyclines in intermediate and high-risk HER2-negative early breast cancer-a pooled analysis of the randomised clinical trials PlanB and SUCCESS C.
In: British Journal of Cancer, Bd. 126, Nr. 12: S. 1715-1724
Gluz, Oleg; Nitz, Ulrike; Kolberg-Liedtke, Cornelia; Prat, Aleix; Christgen, Matthias; Kuemmel, Sherko; Mohammadian, Mohammad Parsa; Gebauer, Daniel; Kates, Ronald; Pare, Laia; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Wuerstlein, Rachel; Graeser, Monika; Pelz, Enrico; Jozwiak, Katarzyna; Zu Eulenburg, Christine; Kreipe, Hans Heinrich und Harbeck, Nadia
(2022):
De-escalated Neoadjuvant Chemotherapy in Early Triple-Negative Breast Cancer (TNBC): Impact of Molecular Markers and Final Survival Analysis of the WSG-ADAPT-TN Trial.
In: Clinical Cancer Research, Bd. 28, Nr. 22: S. 4995-5003
Kolberg-Liedtke, Cornelia; Feuerhake, Friedrich; Garke, Madlen; Christgen, Matthias; Kates, Ronald; Grischke, Eva Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Kuemmel, Sherko; Wuerstlein, Rachel; Graeser, Monika; Nitz, Ulrike; Kreipe, Hans; Gluz, Oleg und Harbeck, Nadia
(2022):
Impact of stromal tumor-infiltrating lymphocytes (sTILs) on response to neoadjuvant chemotherapy in triple-negative early breast cancer in the WSG-ADAPT TN trial.
In: Breast Cancer Research, Bd. 24, Nr. 1, 58
Graeser, Monika; Feuerhake, Friedrich; Gluz, Oleg; Volk, Valery; Hauptmann, Michael; Jozwiak, Katarzyna; Christgen, Matthias; Kuemmel, Sherko; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Kolberg-Liedtke, Cornelia; Kates, Ronald; Wuerstlein, Rachel; Nitz, Ulrike; Kreipe, Hans Heinrich und Harbeck, Nadia
(2021):
Immune cell composition and functional marker dynamics from multiplexed immunohistochemistry to predict response to neoadjuvant chemotherapy in the WSG-ADAPT-TN trial.
In: Journal for Immunotherapy of Cancer, Bd. 9, Nr. 5, e002198
Grote, Isabel; Bartels, Stephan; Kandt, Leonie; Bollmann, Laura; Christgen, Henriette; Gronewold, Malte; Raap, Mieke; Lehmann, Ulrich; Gluz, Oleg; Nitz, Ulrike; Kuemmel, Sherko; Zu Eulenburg, Christine; Braun, Michael; Aktas, Bahriye; Grischke, Eva-Maria; Schumacher, Claudia; Luedtke-Heckenkamp, Kerstin; Kates, Ronald; Wuerstlein, Rachel; Graeser, Monika; Harbeck, Nadia; Christgen, Matthias und Kreipe, Hans
(2021):
TP53 mutations are associated with primary endocrine resistance in luminal early breast cancer.
In: Cancer Medicine, Bd. 10, Nr. 23: S. 8581-8594
Ni, Hua; Kumbrink, Jörg; Mayr, Doris; Seiler, Alina; Hagemann, Friederike; Degenhardt, Tom; Sagebiel, Sabine; Würstlein, Rachel; Kates, Ronald; Harbeck, Nadia und Eggersmann, Tanja K.
(2021):
Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast Cancer.
In: Journal of Personalized Medicine, Bd. 11, Nr. 9, 835
Gluz, Oleg; Kolberg-Liedtke, Cornelia; Prat, Aleix; Christgen, Matthias; Gebauer, Daniel; Kates, Ronald; Pare, Laia; Grischke, Eva-Maria; Forstbauer, Helmut; Braun, Michael; Warm, Mathias; Hackmann, John; Uleer, Christoph; Aktas, Bahriye; Schumacher, Claudia; Kuemmel, Sherko; Würstlein, Rachel; Pelz, Enrico; Nitz, Ulrike; Kreipe, Hans Heinrich und Harbeck, Nadia
(2020):
Efficacy of deescalated chemotherapy according to PAM50 subtypes, immune and proliferation genes in triple-negative early breast cancer: Primary translational analysis of the WSG-ADAPT-TN trial.
In: International Journal of Cancer, Bd. 146, Nr. 1: S. 262-271
Dowsett, Mitch; Ellis, Matthew J. 
ORCID: https://orcid.org/0000-0002-8467-8534; Dixon, J. Michael; Gluz, Oleg; Robertson, John; Kates, Ronald; Suman, Vera J.; Turnbull, Arran K.; Nitz, Ulrike; Christgen, Matthias; Kreipe, Hans; Kuemmel, Sherko; Bliss, Judith M.; Barry, Peter; Johnston, Stephen R.; Jacobs, Samuel A.; Ma, Cynthia X.; Smith, Ian E. und Harbeck, Nadia ORCID: https://orcid.org/0000-0002-9744-7372
(2020):
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
In: Npj Breast Cancer, Bd. 6, Nr. 1, 21: S. 1-10
[PDF, 1MB]
ORCID: https://orcid.org/0000-0002-8467-8534; Dixon, J. Michael; Gluz, Oleg; Robertson, John; Kates, Ronald; Suman, Vera J.; Turnbull, Arran K.; Nitz, Ulrike; Christgen, Matthias; Kreipe, Hans; Kuemmel, Sherko; Bliss, Judith M.; Barry, Peter; Johnston, Stephen R.; Jacobs, Samuel A.; Ma, Cynthia X.; Smith, Ian E. und Harbeck, Nadia ORCID: https://orcid.org/0000-0002-9744-7372
(2020):
Evidence-based guidelines for managing patients with primary ER+ HER2- breast cancer deferred from surgery due to the COVID-19 pandemic.
In: Npj Breast Cancer, Bd. 6, Nr. 1, 21: S. 1-10
[PDF, 1MB]
Kolberg-Liedtke, Cornelia; Gluz, Oleg; Heinisch, Fred; Feuerhake, Friedrich; Kreipe, Hans; Clemens; Nuding, Benno; Malter, Wolfram; Reimer, Tora; Würstlein, Rachel; Graeser, Monika; Shak, Steve; Nitz, Ulrike; Kates, Ronald; Christgen, Matthias und Harbeck, Nadia
(2020):
Association of TILs with clinical parameters, Recurrence Score (R) results, and prognosis in patients with early HER2-negative breast cancer (BC)-a translational analysis of the prospective WSG PlanB trial.
In: Breast Cancer Research, Bd. 22, Nr. 1, 47
Griguolo, Gaia; Braso-Maristany, Fara; Gonzalez-Farre, Blanca; Pascual, Tomas; Chic, Nuria; Sauri, Tamara; Kates, Ronald; Gluz, Oleg; Martinez, Debora; Pare, Laia; Tsvetkova, Vassilena; Pesantez, David; Vidal, Maria; Adamo, Barbara; Munoz, Montserrat; Galvan, Patricia; Barbera, Laura; Cuatrecasas, Miriam; Christgen, Mathias; Kreipe, Hans; Monge-Escartin, Ines; Villagrasa, Patricia; Soy, Dolors; Giarratano, Tommaso; Dieci, Maria Vittoria; Conte, Pierfranco; Harbeck, Nadia; Guarneri, Valentina und Prat, Aleix
(2020):
ERBB2mRNA Expression and Response to Ado-Trastuzumab Emtansine (T-DM1) in HER2-Positive Breast Cancer.
In: Cancers, Bd. 12, Nr. 7, 1902
Raap, Mieke; Gronewold, Malte; Christgen, Henriette; Glage, Silke; Bentires-Alj, Mohammad; Koren, Shany; Derksen, Patrick W.; Bölens, Mirjam; Jonkers, Jos; Lehmann, Ulrich; Feuerhake, Friedrich; Kühnle, Elna; Gluz, Oleg; Kates, Ronald; Nitz, Ulrike; Harbeck, Nadia; Kreipe, Hans H. und Christgen, Matthias
(2018):
Lobular carcinoma in situ and invasive lobular breast cancer are characterized by enhanced expression of transcription factor AP-2 beta.
In: Laboratory Investigation, Bd. 98, Nr. 1: S. 117-129
Marguet, Sophie; Mazouni, Chafika; Ramaekers, Bram L. T.; Dunant, Ariane; Kates, Ronald; Jacobs, Volker R.; Joore, Manuela A.; Harbeck, Nadia und Bonastre, Julia
(2016):
European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer.
In: European Journal of Cancer, Bd. 63: S. 168-179
Schouten, Philip C.; Gluz, Oleg; Harbeck, Nadia; Mohrmann, Svjetlana; Diallo-Danebrock, Raihana; Pelz, Enrico; Kruizinga, Janneke; Velds, Arno; Nieuwland, Marja; Kerkhoven, Ron M.; Liedtke, Cornelia; Frick, Markus; Kates, Ronald; Linn, Sabine C.; Nitz, Ulrike und Marme, Frederik
(2016):
BRCA1-like profile predicts benefit of tandem high dose epirubicin-cyclophospamide-thiotepa in high risk breast cancer patients randomized in the WSG-AM01 trial.
In: International Journal of Cancer, Bd. 139, Nr. 4: S. 882-889